Janux Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 17.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.09B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008...